Core Viewpoint - Shanghai Kaibao (300039.SZ) announced that it and its wholly-owned subsidiary, Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., have a total of 92 drugs included in the National Medical Insurance Directory, with 50 classified as Category A and 42 as Category B [1] Group 1: Drug Inclusion in National Medical Insurance Directory - The company has three exclusive products (Tanreqing Injection, Tanreqing Capsules, and Qishen Capsules) and one exclusive dosage form (Duo Suo Tea Alkaloid Capsules) continuing in the National Medical Insurance Directory (2025) [1] - The company's products Linggui Zhugan Decoction Granules, Yiguan Decoction Granules, and the subsidiary's Duo Suo Tea Alkaloid Tablets are included in the National Medical Insurance Directory (2025) [1] - The exclusive product Tanreqing Capsules remains in the National Medical Insurance Directory (2025) with a reimbursement standard of 4.09 yuan per (0.4g/piece), valid from January 1, 2026, to December 31, 2027 [1] Group 2: Changes in Drug Status - The subsidiary's products, Compound Robama Tablets and Baldness Pills, have been removed from the National Medical Insurance Directory (2025) [1] - Currently, the removal of the aforementioned products from the insurance directory has no substantial impact on the company's operating performance [1] - Other products' inclusion in the National Medical Insurance Directory (2025) remains unchanged compared to the National Medical Insurance Directory (2024) [1]

Core Viewpoint - Shanghai Kaibao (300039.SZ) announced that it and its wholly-owned subsidiary, Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., have a total of 92 drugs included in the National Medical Insurance Directory, with 50 classified as Category A and 42 as Category B [1] Group 1 - The company has three exclusive products (Tan Re Qing injection, Tan Re Qing capsules, and Qi Shen capsules from the subsidiary) and one exclusive dosage form (Duo Suo Tea Alkaloid capsules) that continue to be included in the National Medical Insurance Directory (2025) [1] - The company's products Ling Gui Zhu Gan Tang granules, Yi Guan Jian granules, and the subsidiary's Duo Suo Tea Alkaloid tablets are also listed in the National Medical Insurance Directory (2025) [1] - The exclusive product Tan Re Qing capsules remains in the National Medical Insurance Directory (2025) with a reimbursement standard of 4.09 yuan per (0.4g/piece), with the agreement valid from January 1, 2026, to December 31, 2027 [1] Group 2 - The subsidiary's products, Compound Luo Bu Ma tablets and Ban Hu Wan, have been removed from the National Medical Insurance Directory (2025), but this adjustment has no substantial impact on the company's operating performance [1] - Other products' inclusion in the National Medical Insurance Directory (2025) remains unchanged compared to the National Medical Insurance Directory (2024) [1]

Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

Group 1 - The core point of the article is that Kang En Bei has received approval from the National Medical Products Administration for the drug registration certificate of Ling Gui Zhu Gan Decoction Granules [2] Group 2 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical market [2] - The announcement was made on the evening of September 3, indicating a timely update for stakeholders [2] - This development may lead to increased market opportunities and revenue growth for the company in the future [2]

Core Viewpoint - Kang En Bei (600572) has received approval from the National Medical Products Administration for the registration certificate of Ling Gui Zhu Gan Decoction Granules, which are indicated for treating phlegm-dampness due to deficiency of middle yang [1] Company Summary - The newly approved product, Ling Gui Zhu Gan Decoction Granules, is noted for its effects of warming yang, promoting fluid metabolism, and strengthening the spleen to eliminate dampness [1]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The core point of the article is that Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Linggui Zhugan Decoction Granules, which is expected to positively impact the company's performance [1][2]. - The drug is classified as a traditional Chinese medicine (Category 3.1) and is intended for the treatment of symptoms related to insufficient middle yang and phlegm-dampness [1][2]. - The company has invested approximately 12.7 million RMB in the research and development of this drug [2]. Group 2 - As of the announcement date, there are four approved drug registration numbers for Linggui Zhugan Decoction Granules, with the company being the fourth to receive approval [2]. - The market for cardiovascular disease medications, including traditional Chinese medicine, reached a total sales amount of 50.431 billion RMB in 2024, showing a year-on-year decline of 3.10% [2]. - The sales amount for Linggui Zhugan Decoction Granules in 2024 was reported to be 210,000 RMB, following its market entry in December 2022 [2].

Core Viewpoint - Kang En Bei (600572) has received approval from the National Medical Products Administration for the registration certificate of Ling Gui Zhu Gan Decoction Granules, which is derived from the Han Dynasty text "Jin Kui Yao Lue" and is indicated for treating phlegm-dampness due to deficiency of middle yang [1] Group 1 - The approval of the drug registration certificate marks a significant milestone for the company, enhancing its product portfolio in traditional Chinese medicine [1] - Ling Gui Zhu Gan Decoction Granules are known for their efficacy in warming yang, transforming phlegm, and benefiting the spleen and dampness [1] - The product is specifically indicated for conditions related to insufficient middle yang and phlegm accumulation [1]

Core Viewpoint - The company Kangnibei (600572.SH) has received approval from the National Medical Products Administration for the registration certificate of Linggui Zhugan Decoction Granules, indicating a significant advancement in its product offerings [1] Group 1: Product Information - Linggui Zhugan Decoction Granules are derived from Zhang Zhongjing's "Jinkui Yaolue" from the Han Dynasty, known for its warming, diuretic, and spleen-strengthening effects [1] - The decoction is indicated for conditions related to insufficient middle yang and phlegm retention, with symptoms including fullness in the chest and flanks, dizziness, palpitations, shortness of breath, cough, white and slippery tongue coating, and wiry and slippery pulse [1] - The formula consists of four key ingredients: Poria, Cinnamon Twig, Atractylodes, and Licorice [1]